Rheumatoid Arthritis (Immunology) Drugs Development Research Report 2021 – ResearchAndMarkets.com

Rheumatoid Arthritis (Immunology) Drugs Development Research Report 2021 – ResearchAndMarkets.com

Rheumatoid Arthritis (Immunology) Drugs Development Research Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Rheumatoid Arthritis (Immunology) – Drugs in Development, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Rheumatoid Arthritis – Drugs in Development, 2021, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Rheumatoid Arthritis – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 3, 29, 43, 72, 8, 208, 63 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 6, 28 and 2 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Key Topics Covered:

  • Rheumatoid Arthritis – Therapeutics Development
  • Rheumatoid Arthritis – Therapeutics Assessment
  • Rheumatoid Arthritis – Companies Involved in Therapeutics Development
  • Rheumatoid Arthritis – Drug Profiles
  • Rheumatoid Arthritis – Dormant Projects
  • Rheumatoid Arthritis – Discontinued Products
  • Rheumatoid Arthritis – Product Development Milestones
  • Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/h78nyc



Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900